HealthEquity stock has delivered a 61.0% return over the past 5 years, yet the valuation signals are split, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to meaningful upside while earnings based multiples suggest the shares screen as expensive.

• Over the past 5 years, HealthEquity has returned 61.0%, which puts more focus on whether the current price still offers a margin of safety.
• Expectations around HealthEquity's ability to convert its revenue base into consistent cash flows can support the intrinsic value case, while any pressure on margins or slower growth in account and asset levels may weigh on what investors are willing to pay.
• HealthEquity scores 2 out of 6 on our broader valuation checks, which suggests the stock does not screen as a clear bargain overall even though some metrics look attractive; see the detailed valuation breakdown.

The issue now is whether investors should treat the DCF based upside or the richer market multiples as the more reliable guide to where HealthEquity is priced today.

Is HealthEquity a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) method estimates what HealthEquity could be worth based on the cash it is expected to generate for shareholders over time. For HealthEquity, the model uses latest twelve month free cash flow of about $265.7 million and assumes that cash flows continue to grow rather than shrink.

On those assumptions, the 2 Stage Free Cash Flow to Equity model arrives at an estimated intrinsic value of about $173.90 per share. This is higher than the current share price, which implies a discount of roughly 39.8%. That gap suggests the market is pricing HealthEquity below the level implied by its projected cash generation, even after applying the usual discounting for risk and time.

On this Discounted Cash Flow view, HealthEquity stock currently screens as undervalued.

Our Discounted Cash Flow (DCF) analysis suggests HealthEquity is undervalued by 39.8%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Has HealthEquity Run Too Far on Earnings?

The P/E ratio is a useful way to check what you are paying for each dollar of HealthEquity earnings. HealthEquity currently trades at about 37.9x earnings, which is close to the peer average of 36.5x but well above the broader Healthcare sector average of about 24.9x.

The tailored fair P/E for HealthEquity is estimated at 26.9x based on its profile, which is lower than both the current multiple and the peer average. That gap suggests investors are already paying a premium for HealthEquity relative to what this framework implies, even before considering any further shifts in sentiment or business performance.

On this earnings based view, HealthEquity stock appears overvalued compared with the P/E level suggested by its fundamentals.

The HealthEquity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this HealthEquity valuation puzzle leaves off. They spell out which assumptions about HealthEquity's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and sit on Simply Wall St's Community page. Rather than relying on a single multiple or model, each narrative lays out its own set of assumptions so you can compare them with actual results over time.

You can add your voice to the Simply Wall St community by sharing a Narrative on HealthEquity that lays out your numbers based view on where its growth, margins and execution go from here. Set out your thesis, track how it plays out against future results, and see how other investors respond to your take on HealthEquity's valuation story.

Do you think there's more to the story for HealthEquity? Head over to our Community to see what others are saying!

The Bottom Line

HealthEquity sits between two conflicting valuation signals. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the P/E based view screens the stock as overvalued relative to its tailored fair multiple. The broader valuation checks are weak, which tempers confidence in the DCF signal on its own. The core question from here is whether HealthEquity can translate its revenue base into resilient cash flows that justify a higher intrinsic value, or whether margins, growth in accounts and assets, and sentiment keep the market multiple capped where it is.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.